[go: up one dir, main page]

UY25821A1 - Preparaciones de una combinación farmacéutica de carvedilol e hidroclorotiazida - Google Patents

Preparaciones de una combinación farmacéutica de carvedilol e hidroclorotiazida

Info

Publication number
UY25821A1
UY25821A1 UY25821A UY25821A UY25821A1 UY 25821 A1 UY25821 A1 UY 25821A1 UY 25821 A UY25821 A UY 25821A UY 25821 A UY25821 A UY 25821A UY 25821 A1 UY25821 A1 UY 25821A1
Authority
UY
Uruguay
Prior art keywords
carvedilol
pharmaceutical combination
hydrochlorotiazide
preparations
hydrochlorothiazide
Prior art date
Application number
UY25821A
Other languages
English (en)
Inventor
Rudolf Heller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25821(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY25821A1 publication Critical patent/UY25821A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una preparación de una combinación farmacéutica para el tratamiento de trastornos cardíacos y cardiovasculares tales como hipertensión, angina de pecho, insuficiencia cardíaca y enfermedades relacionadas, que contiene las substancias activas carvedilol o una sal farmacéuticamente aceptable del mismo e hidroclorotiazida o una sal farmacéuticamente aceptable de la misma, así como aditivos usuales farmacéuticamente. El proceso de producción para la preparación de la combninación, puede comprender los pasos de producción del granulado de carvedilol, de hidroclorotiazida, tratamiento de ambos granulados hasta obtener una masa prensada con una humedad de 6 a20% y una densidad de granel entre 0.1 y 1.5 g/ml
UY25821A 1998-11-27 1999-11-26 Preparaciones de una combinación farmacéutica de carvedilol e hidroclorotiazida UY25821A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98122489 1998-11-27

Publications (1)

Publication Number Publication Date
UY25821A1 true UY25821A1 (es) 2001-07-31

Family

ID=8233041

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25821A UY25821A1 (es) 1998-11-27 1999-11-26 Preparaciones de una combinación farmacéutica de carvedilol e hidroclorotiazida

Country Status (22)

Country Link
US (3) US6403579B1 (es)
EP (1) EP1131072B1 (es)
JP (2) JP2002531395A (es)
KR (1) KR100421347B1 (es)
CN (1) CN1184971C (es)
AR (1) AR020287A1 (es)
AT (1) ATE238056T1 (es)
AU (1) AU765977B2 (es)
BR (1) BR9915610A (es)
CA (1) CA2352361C (es)
CO (1) CO5011053A1 (es)
DE (1) DE69907252T2 (es)
DK (1) DK1131072T3 (es)
ES (1) ES2195638T3 (es)
MY (1) MY121831A (es)
PE (1) PE20001302A1 (es)
PT (1) PT1131072E (es)
TR (3) TR200101470T2 (es)
TW (1) TWI228414B (es)
UY (1) UY25821A1 (es)
WO (1) WO2000032174A2 (es)
ZA (1) ZA200104280B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
EP1335707A4 (en) * 2000-10-24 2005-07-06 Smithkline Beecham Corp NEW CARVEDILOL FORMULATIONS
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
IN191028B (es) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
EP1539140A4 (en) 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
KR20110134952A (ko) 2002-06-27 2011-12-15 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
EP1562552A1 (en) 2002-11-08 2005-08-17 Egalet A/S Controlled release carvedilol compositions
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
US7468442B2 (en) * 2003-04-21 2008-12-23 Matrix Laboratories Ltd. Process for the preparation of carvedilol form-II
AU2003272851A1 (en) * 2003-09-26 2005-04-14 Shuyi Zhang Sustained release preparation containing hydrochlorothiazide
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
JP2007512372A (ja) 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
JP2007513114A (ja) * 2003-12-02 2007-05-24 ニコックス エス エイ 抗高血圧薬としてのカルベジロール及びその他のベータ遮断薬のニトロオキシ誘導体
RU2007129642A (ru) * 2005-02-25 2009-03-27 Ф.Хоффманн-Ля Рош Аг (Ch) Таблетки с улучшенным распределением лекарственного вещества
ES2523729T3 (es) 2006-06-16 2014-12-01 Lek Pharmaceuticals D.D. Composición farmacéutica que comprende hidroclorotiazida y telmisartán
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
BR112012022775A2 (pt) * 2010-03-10 2016-07-19 Nogra Pharma Ltd composições para a lavagem, do cólon e métodos para a produção e utilização das mesmas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
DE69207656T2 (de) * 1991-01-30 1996-10-17 The Wellcome Foundation Ltd., London Wasserlösliche tabletten
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2752162B1 (fr) * 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida

Also Published As

Publication number Publication date
CN1328460A (zh) 2001-12-26
CN1184971C (zh) 2005-01-19
WO2000032174A3 (en) 2000-11-16
WO2000032174A2 (en) 2000-06-08
AR020287A1 (es) 2002-05-02
PE20001302A1 (es) 2000-11-30
DE69907252D1 (de) 2003-05-28
PT1131072E (pt) 2003-08-29
EP1131072B1 (en) 2003-04-23
DE69907252T2 (de) 2004-01-29
ZA200104280B (en) 2002-08-26
JP2002531395A (ja) 2002-09-24
CA2352361C (en) 2007-01-02
JP2007077160A (ja) 2007-03-29
TR200101470T2 (tr) 2001-11-21
BR9915610A (pt) 2001-08-14
TR200200981T2 (tr) 2002-06-21
US6403579B1 (en) 2002-06-11
TWI228414B (en) 2005-03-01
US20020052367A1 (en) 2002-05-02
CA2352361A1 (en) 2000-06-08
ATE238056T1 (de) 2003-05-15
AU1506500A (en) 2000-06-19
KR20010080578A (ko) 2001-08-22
KR100421347B1 (ko) 2004-03-06
CO5011053A1 (es) 2001-02-28
MY121831A (en) 2006-02-28
AU765977B2 (en) 2003-10-09
ES2195638T3 (es) 2003-12-01
EP1131072A2 (en) 2001-09-12
DK1131072T3 (da) 2003-08-11
TR200200982T2 (tr) 2002-06-21
US20040087578A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
UY25821A1 (es) Preparaciones de una combinación farmacéutica de carvedilol e hidroclorotiazida
KR20080086527A (ko) 아미노이소인돌린 화합물을 사용하여 피부 루푸스를치료하는 방법
CR9842A (es) Composiciones de celecoxib
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
ES2091737T3 (es) Formulaciones farmaceuticas de fluoxetina.
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
RU94040864A (ru) Конденсированные индольные производные, их получение, фармацевтическая композиция
SK281947B6 (sk) Použitie farmaceutických preparátov na báze kurkumínu
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
AU6434600A (en) Biphenyl derivatives, production thereof and use as medicines
ES2173868T3 (es) Utilizacion de relaxina para la fabricacion de un medicamento destinado al tratamiento de enfermedades cardiovasculares.
KR20150126618A (ko) 아프레밀라스트를 사용하는 건선성 관절염의 치료
ES2149979T3 (es) Composicion estabilizada para la administracion oral de peptidos.
ATE243504T1 (de) Cefadroxilmonohydrat tablettenformulierung
BR9807992A (pt) Comprimidos para engolir os quais compreendem paracetamol
CZ177397A3 (en) Use of frank incense for preparing a medicament for prophylactic and therapeutic treatment of alzheimer's disease
EA003251B1 (ru) ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ п-АМИНОФЕНОЛА ДЛЯ ПРИГОТОВЛЕНИЯ ФАРМАЦЕВТИЧЕСКИХ КОМПОЗИЦИЙ, ИСПОЛЬЗУЕМЫХ ПРИ ЛЕЧЕНИИ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
WO2018094974A1 (zh) 治疗缺血性脑中风的药物及其制备方法与用途
SE8901003D0 (sv) Snabbloesliga preparat
FI945313A0 (fi) Parannetun biokäytettävyyden omaavat tabletit, jotka sisältävät dikloorimetyleenifosfonihappoa vaikuttavana aineena
HUT57204A (en) Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20081201